Target Information

Target General Infomation
Target ID
T95385
Former ID
TTDI01746
Target Name
Interleukin-12 ligand
Gene Name
IL12B
Synonyms
CLMF p40; Cytotoxic lymphocyte maturation factor 40 kDa subunit; IL12 subunit p40; Interleukin12 subunit beta; NK cell stimulatory factor chain 2; NKSF2; IL12B
Target Type
Clinical Trial
Disease Breast cancer [ICD9: 174, 175; ICD10: C50]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Crohn's disease [ICD9: 555; ICD10: K50]
Fallopian tube cancer; Peritoneal cancer; Ovarian cancer [ICD9:140-229, 183.2, 221.0, 183; ICD10: C57, D28, C56]
Melanoma [ICD9: 172; ICD10: C43]
Moderate-to-severe plaque psoriasis [ICD9: 696; ICD10: L40]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Function
Cytokine that can act as a growthfactor for activated T and NK cells, enhance the lytic activity of NK/lymphokine- activated Killer cells, and stimulate the production of IFN-gamma by resting PBMC.
BioChemical Class
Cytokine: interleukin
UniProt ID
P29460
Sequence
MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW
TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ
KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV
RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN
LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC
RKNASISVRAQDRYYSSSWSEWASVPCS
Structure
1F42; 1F45; 3D85; 3D87; 3DUH; 3HMX; 3QWR; 4GRW; 4OE8; 4OG9; 1F45; 3HMX
Drugs and Mode of Action
Drug(s) ABT-874 Drug Info Phase 3 Moderate-to-severe plaque psoriasis [536651]
Ad-RTS-IL-12 Drug Info Phase 2 Melanoma [549191]
EGEN-001 Drug Info Phase 2 Fallopian tube cancer; Peritoneal cancer; Ovarian cancer [523029]
SFV IL-12 gene therapy Drug Info Phase 2 Breast cancer [549384]
Ad-IL-12 DNA therapeutic Drug Info Phase 1/2 Melanoma [549935]
ABT-874 Drug Info Phase 1 Rheumatoid arthritis [536651]
AS1409 Drug Info Phase 1 Melanoma [531416]
NHS-IL 12 Drug Info Phase 1 Cancer [523590]
ABT-874 Drug Info Discontinued in Phase 2 Crohn's disease [536651]
Modulator ABT-874 Drug Info
Ad-IL-12 DNA therapeutic Drug Info [550477]
Ad-RTS-IL-12 Drug Info [544396]
AS1409 Drug Info [551085]
EGEN-001 Drug Info [550403]
NHS-IL 12 Drug Info [532724]
SFV IL-12 gene therapy Drug Info [551741]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Jak-STAT signaling pathway
Type I diabetes mellitus
Pertussis
Legionellosis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Tuberculosis
Measles
Influenza A
Herpes simplex infection
Inflammatory bowel disease (IBD)
Allograft rejection
WikiPathways Toll-like receptor signaling pathway
Aryl Hydrocarbon Receptor Pathway
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 523029ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth.
Ref 523590ClinicalTrials.gov (NCT01417546) NHS-IL12 for Solid Tumors. U.S. National Institutes of Health.
Ref 531416A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
Ref 536651Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
Ref 549191Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)
Ref 549384Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036273)
Ref 549935Clinical pipeline report, company report or official report of ZIOPHARM.
Ref 532724The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84.
Ref 544396Interleukin 12: still a promising candidate for tumor immunotherapy?. Cancer Immunol Immunother. 2014; 63(5): 419-435.
Ref 550403National Cancer Institute Drug Dictionary (drug id 454593).
Ref 550477National Cancer Institute Drug Dictionary (drug id 710508).
Ref 551085A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
Ref 551741Clinical pipeline report, company report or official report of Trademarkia.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.